Inclusion Criteria:~1. age 55 to 85 years;~2. should have a mild-to-moderate AD diagnosis (MMSE 10-26
inclusive);~3. should have evidence of elevated cortical amyloid by PET using florbetapir F18 (Amyvid) \[i.e. a
positive scan\], assessed qualitatively according to the Amyvid product label.~4. if on anti-dementia treatment
should be on stable treatment for at least 2 months (i.e. cholinesterase inhibitor and/or Memantine or
Axona);~5. stable on all other medications for at least 30 days prior to screen;~6. should be fluent in
English;~7. should be physically able to participate by medical history, clinical exam and tests;~8. should
have a study partner to accompany them to scheduled visits.~
